ERYTHRODERMIC PSORIASIS
Clinical trials for ERYTHRODERMIC PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new ERYTHRODERMIC PSORIASIS trials appear
Sign up with your email to follow new studies for ERYTHRODERMIC PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for rare, severe psoriasis
Disease control OngoingThis phase 3 trial tests an oral drug called JNJ-77242113 in 19 people with two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. The study measures how many participants see improvement after 16 weeks of treatment. It is an open-labe…
Matched conditions: ERYTHRODERMIC PSORIASIS
Phase: PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug TAK-279 targets rare, severe psoriasis in phase 3 trial
Disease control OngoingThis phase 3 trial tests the drug TAK-279 in 18 adults with generalized pustular psoriasis or erythrodermic psoriasis, two rare and severe forms of the disease. All participants receive the drug for up to 52 weeks to see if it clears skin symptoms and is safe. The study is open-l…
Matched conditions: ERYTHRODERMIC PSORIASIS
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC